Search Results | Blood | American Society of Hematology

1-20 of 504

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Outcomes of rare patients with a primary cutaneous CD30 + lymphoproliferative disorder developing extracutaneous disease

Rutger C. Melchers, Rein Willemze, Joost S. P. Vermaat, Patty M. Jansen, Laurien A. Daniëls, Hein Putter, Marcel W. Bekkenk, Ellen R. M. de Haas, Barbara Horvath, Michelle M. van Rossum, Cornelus J. G. Sanders, Joep C. J. M. Veraart, Maarten H. Vermeer, Koen D. Quint

Blood (2020) 135 (10): 769–773.

DOI: https://doi.org/10.1182/blood.2019002799

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab vedotin in the treatment of CD30 + PTCL

Stefan K. Barta, Jerald Z. Gong, Pierluigi Porcu

Blood (2019) 134 (26): 2339–2345.

DOI: https://doi.org/10.1182/blood.2019001821

Published: 2019

Journal Articles

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

Marc Nicolas Bienz, MD MSc, Cheryl Taylor-Kashton, Naciba Benlimame, PhD, Tina Petrogiannis-Haliotis, MD PhD, Kevin Pehr, MD, Sabine Mai, PhD, Hans Knecht, MD

Blood (2019) 134 (Supplement_1): 1501.

DOI: https://doi.org/10.1182/blood-2019-124559

Published: 2019

Journal Articles

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Kirill A. Lyapichev, MD, L. Jeffrey Medeiros, MD, Shaoying Li, MD, C. Cameron Yin, MD PhD, Guilin Tang, MD, M. James You, MD PhD, Sergej Konoplev, Swaminathan P. Iyer, MD, Carlos E. Bueso-Ramos, MD PhD, Roberto N. Miranda, MD, Jie Xu

Blood (2019) 134 (Supplement_1): 1560.

DOI: https://doi.org/10.1182/blood-2019-124556

Published: 2019

Journal Articles

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

Ruetima Titapiwatanakun, MD, Sukhjeet Singh Batth, MD, Katherine Baker, NP, Wendy Tcheng, MD, Karen S. Fernandez, MD

Blood (2019) 134 (Supplement_1): 5298.

DOI: https://doi.org/10.1182/blood-2019-122973

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

DOI: https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Giuseppe Lia, PhD, Clara Di Vito, PhD, Marta Tapparo, PhD, Stefania Bruno, Elisa Zaghi, Michela Calvi, Lucia Brunello, Jacopo Mariotti, MD, Lorenzo Comba, Luisa Giaccone, Martina Fascì, Mario Boccadoro, Andrea Evangelista, MSc, Luca Castagna, MD, Giovanni Camussi, Domenico Mavilio, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 598.

DOI: https://doi.org/10.1182/blood-2019-126521

Published: 2019

Journal Articles

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

Carmina Louise Hugo Guerrero, MS, Yoshiko Yamashita, PhD, Megumi Kuba-Miyara, PhD, Naoki Imaizumi, PhD, Shugo Sakihama, PhD, Masaki Hayashi, MD, Takashi Miyagi, MD PhD, Satoko Morishima, MD PhD, Kennosuke Karube, MD PhD, Yuetsu Tanaka, PhD, Hiroaki Masuzaki, MD PhD, Takuya Fukushima, MD PhD

Blood (2019) 134 (Supplement_1): 660.

DOI: https://doi.org/10.1182/blood-2019-129817

Published: 2019

Journal Articles

Mutational Landscape of Grey Zone Lymphoma

Blood (2019) 134 (Supplement_1): 21.

DOI: https://doi.org/10.1182/blood-2019-127375

Published: 2019

Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, Ajibade O Ashaye, MD MBA, MPH, MSc., Ruchit Shah, PhD, Shelby Corman, PharmD, MS, BCPS, Mehul Dalal, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 3482.

DOI: https://doi.org/10.1182/blood-2019-127289

Published: 2019

Journal Articles

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Blood (2019) 134 (Supplement_1): 2069.

DOI: https://doi.org/10.1182/blood-2019-127969

Published: 2019

Journal Articles

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Guldane Cengiz Seval, Atilla Uslu, MD, Ekin Kircali, Sinem Civriz Bozdag, MD, Klara Dalva, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Isinsu Kuzu, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Osman Ilhan, MD, Hamdi Akan, MD, Meral Beksac, MD, Gunhan Gurman, MD

Blood (2019) 134 (Supplement_1): 2019.

DOI: https://doi.org/10.1182/blood-2019-128750

Published: 2019

Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 238.

DOI: https://doi.org/10.1182/blood-2019-122576

Published: 2019

Journal Articles

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Jennifer Agrusa, MD, Elmoataz A Abdel Fattah, MBBCh, Howard Lin, BS, Rikhia Chakraborty, PhD, Brooks Scull, MS, Harshal Abhyankar, MS, Nmazuo Wudo Ozuah, MBBS, Olive S. Eckstein, MD, Terzah M Horton, MD PhD, Kala Kamdar, MD, Kenneth L. McClain, MD PhD, Chris Tsz-Kwong Man, PhD, Carl E. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2773.

DOI: https://doi.org/10.1182/blood-2019-125982

Published: 2019

Journal Articles

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

Paola Ghione, MD, Peter Cordeiro, MD, Venkatraman Seshan, PhD, Natasha Galasso, Nivetha Ganesan, MPH, Qunying Hu, Ahmet Dogan, MD PhD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2842.

DOI: https://doi.org/10.1182/blood-2019-122572

Published: 2019

Journal Articles

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Nicolas Martinez-Calle, MD MSc, Amy A. Kirkwood, MSc, Maxine Lamb, PhD, Alexandra Smith, PhD, Kate Manos, Caroline Shrubsole, MD, Nicola Gray, Sapna Ladani, MRCP, Katharine Louise Lewis, BMBS, FRCPath, MRCPath, Mark Bishton, Matthew J Ahearne, MDMBBS, Eliza A Hawkes, Wendy Osborne, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Cathy Burton, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 2849.

DOI: https://doi.org/10.1182/blood-2019-122083

Published: 2019

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

DOI: https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Cesar Gentille Sanchez, MD, Joe Ensor, PhD, Akshjot Puri, MD, Jasleen K. Randhawa, MD, Shilpan S. Shah, MD, Sai Ravi Kiran Pingali, MD

Blood (2019) 134 (Supplement_1): 4022.

DOI: https://doi.org/10.1182/blood-2019-131991

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

DOI: https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Wenyu Shi, Jian-Yong Li, MD PhD

Blood (2019) 134 (Supplement_1): 4069.

DOI: https://doi.org/10.1182/blood-2019-130063

Published: 2019

2 3 4 5

NARROW

Outcomes of rare patients with a primary cutaneous CD30 + lymphoproliferative disorder developing extracutaneous disease

Brentuximab vedotin in the treatment of CD30 + PTCL

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

Mutational Landscape of Grey Zone Lymphoma

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only